- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Glenmark reports net profit at Rs 234 crore in Q2
New Delhi: Drug firm Glenmark Pharmaceuticals on Friday reported a consolidated net profit of Rs 233.99 crore for the second quarter ended September 30.The company had posted a net profit of Rs 255.54 crore for the same period previous fiscal, Glenmark said in a BSE filing.Its consolidated revenue stood at Rs 2,952.47 crore for the quarter under consideration. It was Rs 2,815.04 crore for...
New Delhi: Drug firm Glenmark Pharmaceuticals on Friday reported a consolidated net profit of Rs 233.99 crore for the second quarter ended September 30.
The company had posted a net profit of Rs 255.54 crore for the same period previous fiscal, Glenmark said in a BSE filing.
Its consolidated revenue stood at Rs 2,952.47 crore for the quarter under consideration. It was Rs 2,815.04 crore for the same period a year ago, it added.
"The net profit is not comparable on account of forex gain recorded in the previous corresponding quarter of the financial year 19-20," Glenmark said in the regulatory filing.
Commenting on the results, Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said: "Our relentless focus on costs and new product introductions during these challenging times have helped increase revenue and operating profit in the second quarter of this financial year".
India and active pharmaceutical ingredient (API) business performed well along with the Europe and ROW region, he added.
Read also: Glenmark gets USFDA nod to generic version of Rapamune
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751